This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through September 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
medical: Archive
Hims & Hers Advances AI-Powered Personalized Digital Healthcare
by Debanjana Dey
HIMS accelerates AI-powered care with new tech leadership, personalized treatments and a major $870 million investment push.
AMWLNegative Net Change HIMSNegative Net Change DOCSPositive Net Change
medical medical-devices
UNH vs. HUM: Which Healthcare Stock is the Healthier Buy Now?
by Kaibalya Pravo Dey
Humana's sharper Medicare focus, cost discipline and leaner structure position it ahead of UnitedHealth in the healthcare stock race.
UNHPositive Net Change HUMPositive Net Change
healthcare hmo insurance medical
Are Options Traders Betting on a Big Move in Fennec Pharmaceuticals Stock?
by Zacks Equity Research
Investors need to pay close attention to FENC stock based on the movements in the options market lately.
FENCNegative Net Change
medical
BDTX vs. ORIC: Which Oncology Focused Biotech Stock Is a Better Pick Now?
by Ekta Bagri
ORIC's diversified oncology pipeline and positive estimate revisions give it an edge over BDTX's silevertinib-focused strategy.
BDTXPositive Net Change ORICPositive Net Change
biotechnology biotechs medical pharmaceuticals
Boston Scientific Beats on Q3 Earnings, Raises 2025 View, Stock Up
by Zacks Equity Research
BSX posts strong Q3 with 19% EPS growth, lifts 2025 sales and EPS outlook as shares edge higher.
BSXPositive Net Change PODDPositive Net Change PAHCNegative Net Change VCYTNegative Net Change
earnings medical
Universal Health to Report Q3 Earnings: Key Estimates to Note
by Zacks Equity Research
UHS is likely to have posted Q3 revenue and earnings growth, driven by strong hospital and behavioral health segments despite cost pressures.
UHSPositive Net Change CORPositive Net Change EHCPositive Net Change OPCHNegative Net Change
earnings medical
BFLY Q3 Earnings Preview: Strategic Progress Likely to Support Growth
by Zacks Equity Research
Butterfly Network's Q3 earnings may have been shaped by iQ3 adoption, software growth and strategic progress.
IDXXPositive Net Change ANIPNegative Net Change EXASNegative Net Change BFLYNegative Net Change
earnings medical medical-devices
The Zacks Analyst Blog Highlights Moodys, Stryker and CBRE
by Zacks Equity Research
Zacks highlights three wide-moat leaders Moody's, Stryker, and CBRE poised to deliver durable returns through strong fundamentals, innovation, and strategic expansion.
MCOPositive Net Change SYKPositive Net Change CBRENegative Net Change
finance medical reit
Thermo Fisher's Q3 Earnings & Revenues Top Estimates, Stock Climbs
by Zacks Equity Research
TMO delivers robust Q3 results, fueled by margin growth, new launches and AI-focused strategic initiatives.
TMONegative Net Change PODDPositive Net Change PAHCNegative Net Change VCYTNegative Net Change
earnings medical medical-devices
Zacks.com featured highlights include Flux Power, Aura Minerals, Arcturus Therapeutics and Sterling Infrastructure
by Zacks Equity Research
Flux Power, Aura Minerals, Arcturus Therapeutics, and Sterling Infrastructure show strong price momentum amid market uncertainty.
ARCTNegative Net Change STRLNegative Net Change FLUXNegative Net Change AUGONegative Net Change
computers construction industrial-products medical
How to Play Aurora Cannabis Stock Amid Renewed Legalization Hopes?
by Sundeep Ganoria
Aurora Cannabis gains 21% as its medical segment fuels revenue and margin growth, even as recreational sales drag.
TLRYNegative Net Change ACBNegative Net Change CURLFNegative Net Change
marijuana medical
STERIS to Report Q2 Earnings: Here's What to Expect
by Zacks Equity Research
STE is set to post fiscal Q2 results on Nov. 6, with estimates pointing to solid revenue and earnings growth across key segments.
IDXXPositive Net Change STEPositive Net Change ANIPNegative Net Change EXASNegative Net Change
earnings medical
Elevance Health Q3 Earnings Beat Estimates on Strong MA Membership
by Zacks Equity Research
ELV beats EPS estimates by 21% in Q3 as strong Medicare Advantage membership gains and Carelon revenue growth offset Medicaid losses.
ANIPNegative Net Change EXASNegative Net Change ZBHPositive Net Change ELVPositive Net Change
earnings medical
SMMT's Q3 Loss Wider Than Expected, Stock Down on Study Amendments
by Zacks Equity Research
Summit Therapeutics posts a wider Q3 loss as costs surge and investors react to protocol changes in a key ivonescimab study.
MRKPositive Net Change SMMTPositive Net Change ONCPositive Net Change
biotechs earnings medical
Danaher Q3 Earnings Beat Estimates, Life Sciences Sales Up Y/Y
by Zacks Equity Research
DHR Q3 earnings and sales beat estimates, driven by solid segment growth and stronger operating margins.
DHRNegative Net Change FLSNegative Net Change ITTPositive Net Change CIBPositive Net Change
earnings medical
Will Rising Costs Hurt HCA Healthcare Q3 Earnings? Key Estimates Here
by Zacks Equity Research
HCA's Q3 earnings to witness solid revenue growth, but rising expenses may weigh on results.
HCAPositive Net Change SEMNegative Net Change NVSTNegative Net Change ERASPositive Net Change
earnings medical
HIMS Stock Declines Despite Launch of New Specialty in Women's Health
by Zacks Equity Research
Hims & Hers debuts a new women's health specialty, targeting menopause care with personalized treatment plans.
BSXPositive Net Change RMDNegative Net Change MASIPositive Net Change HIMSNegative Net Change
medical medical-devices
4 Stocks Trading Near 52-Week High With More Upside Potential
by Vasundhara Sawalka
Stocks like M, PAHC, WDC and ATRO are seeing price strength and have a high chance of carrying the momentum forward.
MPositive Net Change WDCNegative Net Change ATROPositive Net Change PAHCNegative Net Change
aerospace medical retail tech-stocks
Roche's Gazyva Secures FDA Nod for Label Expansion in Lupus Nephritis
by Zacks Equity Research
RHHBY secures FDA approval to expand Gazyva's label for treating lupus nephritis, offering patients a faster and more convenient treatment option.
ALNYPositive Net Change RHHBYNegative Net Change ANIPNegative Net Change CMMBNegative Net Change
biotechnology biotechs medical pharmaceuticals
NVO's Rybelsus Gets FDA Nod to Reduce Heart Risk in Diabetes Patients
by Zacks Equity Research
Novo Nordisk secures FDA approval for Rybelsus as the first oral GLP-1 therapy proven to cut major heart risks in adults with type II diabetes.
ALNYPositive Net Change NVONegative Net Change ANIPNegative Net Change CMMBNegative Net Change
biotechnology biotechs medical pharmaceuticals
Quest Diagnostics Stock Up on Q3 Earnings & Revenue Beat, Margins Rise
by Zacks Equity Research
DGX posts a strong Q3 with revenues and EPS beating estimates, higher margins and an upbeat full-year outlook.
DGXNegative Net Change PODDPositive Net Change PAHCNegative Net Change VCYTNegative Net Change
earnings medical medical-devices
Buy 3 Wide Moat Stocks to Enhance Your Portfolio Returns in Q4
by Nalak Das
MCO, SYK and CBRE stand out as wide moat stocks with strong growth forecasts and strategic expansions to boost portfolio resilience.
MCOPositive Net Change SYKPositive Net Change CBRENegative Net Change
finance medical reit
Will ISRG's dV5 Lend Momentum to Top Line During Q3 Earnings?
by Indrajit Bandyopadhyay
Intuitive Surgical's new da Vinci 5 is driving strong hospital upgrades and premium pricing, setting up ISRG for potential top-line momentum in Q3.
SYKPositive Net Change ISRGPositive Net Change ZBHPositive Net Change
medical medical-devices
Will BMY's Growth Portfolio Drive Third-Quarter Results?
by Ekta Bagri
Bristol Myers leans on new drugs like Opdivo and Reblozyl to offset pressure from generics as its Growth Portfolio drives stability.
BMYNegative Net Change PFEPositive Net Change MRKPositive Net Change
biotechnology biotechs medical pharmaceuticals
Zimmer Biomet to Report Q3 Earnings: Here's What to Expect
by Zacks Equity Research
ZBH's Q3 results on Nov. 5 may show solid gains, driven by hip, knee, and S.E.T. segment growth and recent product approvals.
IDXXPositive Net Change ANIPNegative Net Change EXASNegative Net Change ZBHPositive Net Change
earnings medical